GleamWall
中文EN

OKUR OnKure Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1637715 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY2.5%
TTM EPS YoY-102.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-55.2%
ROA-51.6%
ROIC (approx.)-4,360.7%
Asset turnover—

Leverage & solvency

Liabilities / assets5.6%
Debt / equity0.00x
Current ratio18.84x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-11.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue—$0
R&D expense$48.26M$43.80M
SG&A expense$14.69M$10.59M
Operating income-$62.95M-$54.39M
Income tax$0$0
Net income-$59.52M-$52.67M
EBITDA-$62.50M-$53.93M
EPS (basic)-4.40-15.28
EPS (diluted)-4.40-15.28
Weighted avg. shares (diluted)13.52M3.45M
Banking
Net interest income$3.43M$1.71M
Balance sheet
Cash & equivalents$59.05M$110.76M
Short-term investments$0—
Current assets$60.84M$113.00M
PP&E, net$618,000$1.02M
Total assets$62.12M$114.91M
Current liabilities$5.92M$10.53M
Total liabilities$5.93M$11.08M
Shareholders' equity$56.18M$103.83M
Cash flow statement
Operating cash flow-$51.83M-$51.12M
Capital expenditure$46,000$52,000
Free cash flow-$51.87M-$51.17M
Investing cash flow-$46,000$15.87M
Financing cash flow$163,000$116.13M
Depreciation & amortization$447,000$459,000
Stock-based compensation$11.63M$4.53M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.